PMV Pharmaceuticals, Inc. (PMVP) Stock Score, Valuation & Financial Research

PMV Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PMVP

PMV Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.61. These figures are a research snapshot, not a buy or sell recommendation.

What PMV Pharmaceuticals, Inc. does

PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

PMV Pharmaceuticals is a clinical-stage precision oncology company that focuses on the discovery and development of small molecule, tumor-agnostic therapies. The company is currently in the research and development phase and has not yet generated revenue from product sales, relying instead on capital raises and financial management to fund its clinical trials.

Products and services

  • The company's primary product candidate is rezatapopt, a small molecule p53 reactivator currently being evaluated in clinical trials for the treatment of patients with genomically-defined cancers.

Brands and product families

  • rezatapopt — Lead product candidate for the treatment of p53-mutated cancers. Source

Customer types

Patients with genomically-defined cancers.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct and manage its clinical trials. Source
  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of its drug candidates. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — Companies that pursue targeted therapies for patients with genomically-defined cancers. Source

Business strengths to evaluate

  • Proprietary platform for targeting p53 mutations Source

Business risks and research considerations

  • Clinical trial failure and regulatory approval uncertainty Source
  • Dependence on third-party manufacturers and clinical trial providers Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PMVP financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.61
Market capitalization:
85.86M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -75.22M
Free cash flow:
USD -73.61M
Cash:
USD 12.47M
Total debt:
USD 217K
EPS:
USD -1.42

What stands out

  • Free cash flow is USD -73.61M, negative for the stored period.
  • The balance sheet shows USD 12.47M of cash versus USD 217K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 12.25M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PMVP

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PMVP fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PMVP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PMVP to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of PMVP's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research PMVP

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.